Search
asfotase alfa (Strensiq)
Indications:
- perinatal, infantile & juvenile-onset hypophosphatasia
Dosage:
- injection 3-6 times per week
Injection: 100 mg/mL (0.8 mL), 40 mg/mL (0.45, 0.7, 1 mL)
Adverse effects:
- most common
- injection site reactions
- hypersensitivity reactions
- dypnea, nausea, dizziness, fever
- lipodystrophy
- ectopic calcifications of the eyes & kidney
Mechanism of action:
- replaces tissue-nonspecific alkaline phosphatase
General
metabolic agent (metabolic modifier)
recombinant protein; chimer
References
- FDA News Release. October 23, 2015
FDA approves new treatment for rare metabolic disorder.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468836.htm